This was also conducted for the six BTK inhibitors in phase II or III trial for MS, using the search terms ‘Multiple Sclerosis’ and ‘BIIB091’, ‘evobrutinib’, ‘fenebrutinib’, ‘orelabrutinib’, ‘remibrutinib’ and ‘tolebrutinib’. The gene discussed is BTK; the disease is myeloid sarcoma.